Futures
Access hundreds of perpetual contracts
TradFi
Gold
One platform for global traditional assets
Options
Hot
Trade European-style vanilla options
Unified Account
Maximize your capital efficiency
Demo Trading
Introduction to Futures Trading
Learn the basics of futures trading
Futures Events
Join events to earn rewards
Demo Trading
Use virtual funds to practice risk-free trading
Launch
CandyDrop
Collect candies to earn airdrops
Launchpool
Quick staking, earn potential new tokens
HODLer Airdrop
Hold GT and get massive airdrops for free
Launchpad
Be early to the next big token project
Alpha Points
Trade on-chain assets and earn airdrops
Futures Points
Earn futures points and claim airdrop rewards
More
LLY Eli Lilly and Company March 16, 2026 RBC Maintains Outperform
RBC Capital has reaffirmed its Outperform rating for Eli Lilly and Company (LLY) on March 16, 2026, driven primarily by the anticipated approval and launch of its drug, Orfo. The analyst firm highlighted Orfo’s potential for market share gains and pricing power as a key upside and expects LLY to outperform its peers over the next year. Meyka AI also assigns LLY an ‘A’ grade, supporting the positive outlook while advising investors to consider valuation, launch execution, and competitive risks.